Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Caribou Biosciences (CRBU) EBT (2020 - 2025)

Caribou Biosciences has reported EBT over the past 6 years, most recently at -$28.5 million for Q4 2025.

  • Quarterly EBT rose 26.81% to -$28.5 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$148.3 million through Dec 2025, up 10.97% year-over-year, with the annual reading at -$148.7 million for FY2025, 0.29% changed from the prior year.
  • EBT was -$28.5 million for Q4 2025 at Caribou Biosciences, up from -$29.4 million in the prior quarter.
  • Over five years, EBT peaked at -$13.2 million in Q1 2021 and troughed at -$47.6 million in Q2 2025.
  • The 5-year median for EBT is -$30.0 million (2022), against an average of -$30.2 million.
  • Year-over-year, EBT crashed 644.59% in 2021 and then surged 44.86% in 2023.
  • A 5-year view of EBT shows it stood at -$18.2 million in 2021, then crashed by 68.4% to -$30.6 million in 2022, then fell by 22.45% to -$37.4 million in 2023, then dropped by 3.83% to -$38.9 million in 2024, then increased by 26.81% to -$28.5 million in 2025.
  • Per Business Quant, the three most recent readings for CRBU's EBT are -$28.5 million (Q4 2025), -$29.4 million (Q3 2025), and -$47.6 million (Q2 2025).